Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma

Conclusion: BV is a highly cost-effective treatment for advanced cutaneous T-cell lymphoma.PMID:34879742 | DOI:10.2217/cer-2021-0201

Source: Journal of Comparative Effectiveness Research - December 9, 2021 Category: General Medicine Authors: Tanja Podkonjak Holly Cranmer Julia Scarisbrick Grant McCarthy Cameron Lilley Lung-I Cheng Source Type: research